Biotechnology News and Research RSS Feed - Biotechnology News and Research

European experts publish common vision of priorities for marine research

European experts publish common vision of priorities for marine research

Some 340 European scientists, policy-makers and other experts representing 143 organizations from 31 countries spoke with one voice today, publishing a common vision of today's most pressing marine-related health and economic threats and opportunities. [More]
RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

Rebiotix Inc. announced today that results of the Phase 2 PUNCH CD Study found that the overall efficacy of RBX2660 in the treatment of recurrent Clostridium difficile infection was 87.1%. The study also found that administration of RBX2660 was well-tolerated and demonstrated satisfactory safety in the 60-day interim analysis. [More]
HemoShear completes first-phase development of novel cancer drug discovery platform

HemoShear completes first-phase development of novel cancer drug discovery platform

HemoShear today announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations. [More]
Scientists say fundamental theory about how thymus educates immune police appears to be wrong

Scientists say fundamental theory about how thymus educates immune police appears to be wrong

A fundamental theory about how our thymus educates our immune police appears to be wrong, scientists say. [More]
Researchers are developing compounds to combat causative agents of periodontitis

Researchers are developing compounds to combat causative agents of periodontitis

A total 12 million Germans suffer from periodontitis. If the inflammation remains untreated, this could lead to tooth loss. However, it is also suspected of triggering many other diseases, like cardiopulmonary diseases. Researchers are studying the interactions, and developing compounds to combat the causative agents. [More]
CSL Behring strengthens global manufacturing capabilities to meet demand for lifesaving therapies

CSL Behring strengthens global manufacturing capabilities to meet demand for lifesaving therapies

CSL Behring today announced a multi-year, $450 million two-site global capacity expansion – the latest in a series of recent production expansions to meet the growing need for its lifesaving and life-improving therapies that are used to treat patients with rare and serious medical disorders around the world. [More]
FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant Gram-positive and Gram-negative pathogens, announced today that the United States Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) as well as Fast Track status designation to Nabriva's lead product lefamulin, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). [More]

OBN, EMIG call on the UK government to allocate additional funding to support BMC programme

OBN and EMIG - organisations with a combined membership of approximately 570 emerging R&D companies in biotechnology and medical technology, and established small and mid-sized biopharmaceutical firms, respectively - have called on the UK government to allocate additional funding to support the industrial component of Innovate UK's Biomedical Catalyst (BMC). [More]
Low sexual desire among women can be treatable

Low sexual desire among women can be treatable

Low sexual desire is common among both pre- and post-menopausal women. It can cause personal distress, harm relationships, and have a negative impact on body image and self confidence. Yet few women seek medical care for this condition, and the reasons are explored in a timely article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. [More]
C3BS inks preferred access agreement with Mayo Clinic

C3BS inks preferred access agreement with Mayo Clinic

Cardio3 BioSciences, a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announces today the signing of a preferred access agreement with Mayo Clinic. [More]
Early potty training linked to increased risk of developing daytime wetting problems later

Early potty training linked to increased risk of developing daytime wetting problems later

Children who start toilet training before age 2 have a three times higher risk of developing daytime wetting problems later, according to new research at Wake Forest Baptist Medical Center. [More]
Absorption Systems supports Pediatric Praziquantel Consortium led by Merck KGaA

Absorption Systems supports Pediatric Praziquantel Consortium led by Merck KGaA

Absorption Systems, a leader in preclinical contract testing of drugs, biologics, and medical devices, announces that it has been subcontracted by the German pharmaceutical company Merck KGaA to work on a new pediatric formulation of praziquantel. [More]
Cognizant announces acquisition of Cadient Group

Cognizant announces acquisition of Cadient Group

Cognizant today announced it has acquired Cadient Group, a full-service digital marketing agency that serves a broad spectrum of life sciences companies in the pharmaceutical, biotechnology, consumer health, and medical device industries. [More]
FDA designates NurOwn as Fast Track product for ALS treatment

FDA designates NurOwn as Fast Track product for ALS treatment

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). [More]
Researchers reveal 'programmable' antibiotic technique to target drug-resistant microbes

Researchers reveal 'programmable' antibiotic technique to target drug-resistant microbes

The multitude of microbes scientists have found populating the human body have good, bad and mostly mysterious implications for our health. But when something goes wrong, we defend ourselves with the undiscriminating brute force of traditional antibiotics, which wipe out everything at once, regardless of the consequences. [More]
New method for extracting potential bone-producing cells from human fat

New method for extracting potential bone-producing cells from human fat

Within our fat lives a variety of cells with the potential to become bone, cartilage, or more fat if properly prompted. This makes adipose tissue, in theory, a readily available reservoir for regenerative therapies such as bone healing if doctors can get enough of those cells and compel them to produce bone. [More]
Novel test could revolutionise discovery of new prescription drugs

Novel test could revolutionise discovery of new prescription drugs

A new test developed by researchers from the University of Manchester could revolutionise the discovery of new prescription drugs. The test will help determine which drugs are unlikely to work at an early stage, speeding up the time it takes to make safe and effective medicines available. [More]

BioCap conference showcased life sciences companies in the North

The unique BioCap conference organised by Bionow, a not for profit membership organisation for the biomedical / life-sciences industry, was a great success, combining the forces of science and financial investment enabling businesses from all over the North to secure essential funding. [More]
Women survivors of sexual abuse may suffer emotional distress during pelvic examination

Women survivors of sexual abuse may suffer emotional distress during pelvic examination

Women who have a history of violent sexual abuse may suffer emotional distress during a routine pelvic examination. Healthcare providers would benefit from greater awareness of symptoms predictive of examination-related distress in this patient population, according to a study published in Violence and Gender, a new peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
NKT Therapeutics' NKTT120 receives FDA Fast Track designation for treatment of sickle cell disease

NKT Therapeutics' NKTT120 receives FDA Fast Track designation for treatment of sickle cell disease

NKT Therapeutics today announced that the U.S. Food and Drug Administration has granted Fast Track designation to NKTT120, the company's lead therapeutic being developed for the treatment of sickle cell disease. [More]